“Luminal A” is a label pathologists use for a pattern of test results: a breast cancer that has hormone receptors (estrogen receptors, progesterone receptors, or both), does not have high levels of the HER2 protein, and shows signs of growing relatively slowly. It is one of the standard ways of grouping breast cancers by their biology, and it sits alongside — not instead of — the other words on your pathology report, such as where the cancer began, its grade, and its stage. If the phrase has appeared on your report and you want it in plain terms, this article explains what each part means.
Key Takeaways
- “Luminal A” describes a pattern: hormone receptors present, HER2 not high, and features that generally suggest slower growth.
- The name comes from the inner lining cells of the breast ducts, called luminal cells, which these cancers most resemble.
- The pattern is read from laboratory tests on the biopsy tissue: hormone receptors, HER2, and a growth marker often called Ki-67.
- Where one laboratory draws the line between “luminal A” and the neighbouring patterns can vary, so your own team reads the label together with your full report.
- Because the cancer has hormone receptors, treatments that act on hormones are among the approaches a team may consider. HER2-directed treatments are generally not part of planning when HER2 is not high.
- Individual cases differ. The label never tells the whole story on its own — stage, grade, and your overall health matter too.
What the Name Means
The breast’s ducts and lobules are lined with cells, and the layer facing the inside of the duct is called the luminal layer. When scientists first grouped breast cancers by which genes they switch on, some cancers looked most like those lining cells, and those groups were named “luminal.” The luminal family has two commonly used members: luminal A and luminal B.
In everyday practice, the label is applied from the standard laboratory results rather than from gene testing. A cancer is generally described as luminal A when the estrogen receptor test is positive (the progesterone receptor test often is too), the HER2 test is not high, and the signs of growth rate point to a slower-growing cancer. Our pillar guide, Types of Breast Cancer Compared, shows how this grouping fits with the other ways a cancer is described.
The word matters because cancers with different biology behave differently and respond to different kinds of treatment. Grouping them helps care teams communicate, compare cases in research, and plan. But a group label is a summary, not a verdict: two cancers can share the luminal A label and still differ in size, stage, and how they are treated.
How the Pattern Is Found on Your Report
Three kinds of laboratory result feed into the luminal A description, and each may appear as its own line on your pathology report:
- Hormone receptors. Tests called immunohistochemistry (IHC) check whether the cancer cells carry receptors for estrogen (ER) and progesterone (PR) — small structures that respond to those hormones. A result of positive means the receptors are present, and the hormones may be among the signals helping the cancer grow.
- HER2. HER2 is a protein on the surface of breast cells that also plays a part in growth. In a luminal A pattern, the HER2 result is in the not-high range — described as HER2-negative or, in the newer vocabulary, sometimes HER2-low. Our article on HER2-low breast cancer explains that label and how it differs from HER2-positive.
- A growth marker. Reports often include a marker called Ki-67, which gives the laboratory a general sense of how many of the cancer cells are actively dividing. In a luminal A pattern this measure is generally at the lower end, which fits with a slower-growing picture. Laboratories do not all draw the lower/higher line in exactly the same place, so treat the label as your team’s reading of the whole set of results rather than a single score.
Grade plays a supporting part too: grade describes how different the cells look from normal cells and how quickly they appear to be growing, and luminal A cancers are often of a lower grade. If your report does not use the words “luminal A” at all, that is common — many reports simply list the receptor results, and the grouping is something your team may refer to in discussion rather than in writing.
How Luminal A Compares With the Other Patterns
The table below sets out the commonly used biology groupings in general terms. It describes test-result patterns only; it is not a ranking of how serious a cancer is, because that depends on the full picture in each individual case.
| Pattern | Hormone receptors | HER2 | Growth pattern, in general |
|---|---|---|---|
| Luminal A | Present | Not high | Generally slower-growing |
| Luminal B | Present (sometimes only weakly) | Not high, or in some definitions high | Generally faster-growing than luminal A |
| HER2-positive (hormone receptor-negative) | Absent | High | Varies |
| Triple-negative | Absent | Not high | Varies |
Notice that the boundaries between the luminal patterns are the softest in the table. A cancer near the boundary may be described slightly differently by different teams, without anyone being wrong — the underlying results are the same, and it is those results, more than the label, that planning is built on. Our comparison of hormone receptor-positive and triple-negative breast cancer may help if you are placing your pattern among the others you have read about.
What It Can Mean for Treatment Planning
The practical importance of the luminal A pattern is the hormone receptors. Because the cancer cells carry them, approaches that block the hormones or lower their levels are among the tools a care team may consider — this is the general approach described in our article on treatment approaches for hormone receptor-positive breast cancer. Because HER2 is not high, HER2-directed treatments are generally not part of the picture.
Whether other treatments, such as chemotherapy, are recommended is a separate and individual judgement. It depends on the cancer’s stage and size, whether lymph nodes are involved, the grade, your age and overall health, and sometimes additional tests your team may discuss with you. This article names no specific medicines and recommends no particular plan, because the right combination and timing belong with your own doctor and care team, who can read the label alongside everything else they know about your case.
It is also worth knowing that a slower-growing pattern does not mean a cancer can be ignored or that follow-up matters less. It is one piece of information among many, and your team’s recommendations — appointments, monitoring, and any treatment — are built from the whole set. If anything about the plan seems inconsistent with what you have read about luminal A, ask your team to talk you through how they weighed the pieces in your case.
Questions to Ask Your Doctor
- Can you walk me through the results that place my cancer in the luminal A group?
- What were my estrogen receptor, progesterone receptor, HER2, and Ki-67 results?
- What were my grade and stage, and how do they fit with this pattern?
- Which parts of my treatment plan follow from the hormone receptors being present?
- How did the team decide whether chemotherapy would or would not help in my case?
- What follow-up and monitoring will I have, and what should I watch for between visits?
- Where can I read reliable general information about these biology groupings?
Frequently Asked Questions
Is luminal A a separate type of breast cancer?
It is a grouping based on biology — the receptor and growth-marker results — rather than a description of where the cancer began. A luminal A cancer can be ductal, lobular, or another type, and the descriptions apply at the same time. Think of it as one layer of your report, not a replacement for the others.
Does luminal A mean my cancer is less serious?
The pattern is generally associated with slower growth, but no single label decides how serious a cancer is. Stage — how large it is and whether it has spread — grade, and how it responds to treatment all matter at least as much. Your care team can explain how the pieces fit together in your own case.
Why does my report not say “luminal A” anywhere?
Many pathology reports list the individual results — ER, PR, HER2, Ki-67 — without applying the group label at all. The grouping is often used in discussion, in research, and in some teams’ planning language. If the individual results match the pattern described here, your team can confirm whether they would use the term for your cancer.
What is the difference between luminal A and luminal B?
Both patterns have hormone receptors. In general, luminal B cancers show signs of faster growth, may have lower progesterone receptor levels, and in some definitions include cancers with high HER2. The line between them is drawn from growth-marker results and is not identical in every laboratory, which is one reason your own team’s reading of your report matters more than the wording in any general article.
Where can I read more?
Our pillar guide compares the main types and patterns side by side. General background on receptor testing and breast cancer biology is also published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov). Your own report, explained by your own team, is the source that matters most.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- HER2-Low Breast Cancer Explained in Plain English
- Hormone Receptor-Positive vs Triple-Negative Breast Cancer
- Treatment Approaches for Hormone Receptor-Positive Breast Cancer
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.